The regulatory state of nonalcoholic steatohepatitis and metabolism

Affiliations

¹ Division of Gastroenterology and Inborn Errors Products (DGIEP) OND CDER U.S. Food and Drug Administration Silver Spring MD USA.
² Division of Metabolism and Endocrinology Products (DMEP) OND CDER U.S. Food and Drug Administration Silver Spring MD USA.

Editorial

Stephanie O Omokaro et al. Endocrinol Diabetes Metab. 2020.

. 2020 Oct 21;3(4):e00113.

doi: 10.1002/edm2.113. eCollection 2020 Oct.

¹ Division of Gastroenterology and Inborn Errors Products (DGIEP) OND CDER U.S. Food and Drug Administration Silver Spring MD USA.
² Division of Metabolism and Endocrinology Products (DMEP) OND CDER U.S. Food and Drug Administration Silver Spring MD USA.

No abstract available

Conflict of interest statement

The authors declared no conflict of interest.

Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease.
Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Fraile JM, et al. Drug Des Devel Ther. 2021 Sep 22;15:3997-4009. doi: 10.2147/DDDT.S315724. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34588764 Free PMC article. Review.
Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.
Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, Wahli W. Rives C, et al. Biomolecules. 2020 Dec 21;10(12):1702. doi: 10.3390/biom10121702. Biomolecules. 2020. PMID: 33371482 Free PMC article. Review.
Machine learning based identification potential feature genes for prediction of drug efficacy in nonalcoholic steatohepatitis animal model.
Matboli M, Abdelbaky I, Khaled A, Khaled R, Hamady S, Farid LM, Abouelkhair MB, El-Attar NE, Farag Fathallah M, Abd El Hamid MS, Elmakromy GM, Ali M. Matboli M, et al. Lipids Health Dis. 2024 Aug 24;23(1):266. doi: 10.1186/s12944-024-02231-9. Lipids Health Dis. 2024. PMID: 39182075 Free PMC article.

1. www.clinicaltrials.gov. Accessed July 31, 2019.
1. FDA . Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics. https://wwwfdagov/media/86377/download. Accessed July 31, 2019.
1. FDA‐CDER .Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment: Guidance for Industry. https://wwwfdagov/media/119044/download . 2018. Accessed July 31, 2019.
1. Docket Folder Summary: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment; FDA Draft Guidance for Industry. https://wwwregulationsgov/docket?D=FDA-2018-D-3632. Docket ID: FDA‐2018‐D‐3632. Accessed July 31, 2019.
1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, MD). 2018;67(1):328‐357. - PubMed